Clinical Trial Update: GT103 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic STK11 Mutant Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating GT103 in combination with pembrolizumab for advanced or metastatic STK11-mutant non-small cell lung cancer is currently recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• GT103
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Roswell Park Cancer Institute | Conditions: Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma | Phase 2 | Status: RECRUITING